TW201402132A - 治療非小細胞肺癌之方法 - Google Patents

治療非小細胞肺癌之方法 Download PDF

Info

Publication number
TW201402132A
TW201402132A TW102117597A TW102117597A TW201402132A TW 201402132 A TW201402132 A TW 201402132A TW 102117597 A TW102117597 A TW 102117597A TW 102117597 A TW102117597 A TW 102117597A TW 201402132 A TW201402132 A TW 201402132A
Authority
TW
Taiwan
Prior art keywords
lung cancer
cell lung
human patient
small cell
nucleotides
Prior art date
Application number
TW102117597A
Other languages
English (en)
Chinese (zh)
Inventor
晨 達辛
秀旭 泰斯勒
Original Assignee
泰瓦藥品工業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 泰瓦藥品工業有限公司 filed Critical 泰瓦藥品工業有限公司
Publication of TW201402132A publication Critical patent/TW201402132A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102117597A 2012-05-18 2013-05-17 治療非小細胞肺癌之方法 TW201402132A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
TW201402132A true TW201402132A (zh) 2014-01-16

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102117597A TW201402132A (zh) 2012-05-18 2013-05-17 治療非小細胞肺癌之方法

Country Status (17)

Country Link
US (1) US20130310440A1 (https=)
EP (1) EP2849761A1 (https=)
JP (1) JP2015522542A (https=)
KR (1) KR20150024843A (https=)
CN (1) CN104684564A (https=)
AR (1) AR091090A1 (https=)
AU (1) AU2013262589A1 (https=)
BR (1) BR112014028787A2 (https=)
CA (1) CA2874092A1 (https=)
EA (1) EA201492148A1 (https=)
IL (1) IL235459A0 (https=)
IN (1) IN2014DN10390A (https=)
PH (1) PH12014502569A1 (https=)
SG (1) SG11201407649RA (https=)
TW (1) TW201402132A (https=)
UY (1) UY34812A (https=)
WO (1) WO2013173757A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
PT4122383T (pt) 2010-05-08 2025-05-02 Univ California Aparelho de deteção de scanner sem para a deteção precoce de úlceras
SG192957A1 (en) 2011-03-15 2013-09-30 Univ British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
AU2016250527B2 (en) 2015-04-24 2021-01-14 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
EP4241670B1 (en) 2017-02-03 2025-12-10 BBI Medical Innovations, LLC Measurement of tissue viability
KR102304070B1 (ko) 2017-02-03 2021-09-23 브루인 바이오메트릭스, 엘엘씨 부종의 측정
US20180220954A1 (en) 2017-02-03 2018-08-09 Bruin Biometrics, Llc Measurement of susceptibility to diabetic foot ulcers
CN116473517A (zh) * 2017-11-16 2023-07-25 布鲁恩生物有限责任公司 使用表皮下水分值对压力性溃疡进行战略治疗
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PL3749181T3 (pl) 2018-02-09 2024-06-10 Bruin Biometrics, Llc Wykrywanie uszkodzenia tkanek
GB2591899B (en) 2018-10-11 2022-03-09 Bruin Biometrics Llc Device with disposable element
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CN102224419A (zh) * 2008-06-18 2011-10-19 雅培制药有限公司 PlGF-1搭配诊断法和产物
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
IL235459A0 (en) 2014-12-31
IN2014DN10390A (https=) 2015-08-14
EA201492148A1 (ru) 2015-04-30
AU2013262589A1 (en) 2015-01-22
KR20150024843A (ko) 2015-03-09
WO2013173757A1 (en) 2013-11-21
AR091090A1 (es) 2014-12-30
EP2849761A1 (en) 2015-03-25
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
US20130310440A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03
PH12014502569A1 (en) 2015-01-21
JP2015522542A (ja) 2015-08-06
UY34812A (es) 2013-12-31
BR112014028787A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
TW201402132A (zh) 治療非小細胞肺癌之方法
Rosell et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Gatzemeier et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
CN103958681A (zh) 治疗非小细胞肺癌的方法
Song et al. Phase I trial of selenium plus chemotherapy in gynecologic cancers
KR20180050426A (ko) 치료제의 약물 전달 및 유효성 향상 방법
KR20150131312A (ko) 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Gauler et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
CN107750165A (zh) 借助塞里班土单抗的组合治疗
McCleary-Wheeler et al. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
TW201130830A (en) Combined treatment of pancreatic cancer with gemcitabine and masitinib
Powell et al. Phase II study of topotecan and bevacizumab in advanced, refractory non–small-cell lung cancer
WO2018138510A1 (en) Mebendazole for use in the treatment of cancer
US9901594B2 (en) Pharmaceutical composition and uses thereof
WO2012106379A1 (en) Sensitization of cancer cells to treatment
CN121969373A (zh) 使用mta协作的prmt5抑制剂的癌症治疗
Jia et al. Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
Roviello et al. A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers
WO2015171973A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitory compound based on chemosensitive status
US20230338347A1 (en) New Use of Inhibitors of the Notch Signalling Pathway
WO2016179702A1 (en) Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers
Stroes Precision oncology in esophagogastric cancer
Mantrana et al. A phase 1b study of CBP501, a novel immunogenic cell death inducer, combined with cisplatin and nivolumab in patients with advanced solid tumors